Overview

The COSMYC Trial (COmbined Suppression of MYC)

Status:
RECRUITING

Trial end date:
2031-08-30

Target enrollment:

Participant gender:

Summary

This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.

Phase:

PHASE2

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators:

National Cancer Institute (NCI)
Zenith Epigenetics

Treatments:

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
enzalutamide
Gonadotropin-Releasing Hormone
Goserelin
Leuprolide
luprolide acetate gel depot
relugolix
testosterone 17 beta-cypionate
Triptorelin Pamoate